Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|33|3656-3661

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.33, 2011-11, pp. : 3656-3661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL

By  

Current Pharmaceutical Design, Vol. 20, Iss. 40, 2014-12 ,pp. : 6256-6269

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease

By  

Current Pharmaceutical Design, Vol. 24, Iss. 3, 2018-04 ,pp. : 291-296

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-Associated Phospholipase A2: How Effective as a Risk Marker of Cardiovascular Disease and as a Therapeutic Target?

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 10, Iss. 4, 2011-01 ,pp. : 236-246

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target

By Macphee Colin   Benson G Martin   Shi Yi   Zalewski Andrew  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 671-679

Informa Healthcare

Access to resources Recommend Favorite

Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque

By Macphee Colin H   Suckling Keith E  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 3, 2002-06 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite